MAIA director granted 26,982 stock options
MAIA Biotechnology, Inc. director Steven M. Chaouki reported a compensation-related grant of stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
MAIA Biotechnology, Inc. director Steven M. Chaouki reported a compensation-related grant of stock options. He received options covering 26,982 shares of common stock at an exercise price of $1.44 per share, granted on June 30, 2026 under the company’s 2021 Equity Incentive Plan.
The options vest 100% on the grant date and are exercisable beginning that date, with an expiration date of June 30, 2036. Following this grant, Chaouki holds 26,982 stock options directly.
Insider Trade Summary
Grant/Award: 26,982 shares
Grant/Award
1 txn
Insider
CHAOUKI STEVEN M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 26,982 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 26,982 contracts (Direct)
Footnotes (1)
- F1. The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Key Figures
Stock options granted: 26,982 options
Underlying shares: 26,982 shares
Exercise price: $1.44 per share
+3 more
6 metrics
Stock options granted
26,982 options
Grant to director Steven M. Chaouki on June 30, 2026
Underlying shares
26,982 shares
Common stock underlying the granted options
Exercise price
$1.44 per share
Strike price for the granted stock options
Expiration date
June 30, 2036
Option term end for this grant
Price at grant
$0.00 per option
No cash paid by director to receive the option award
Post-grant derivative holdings
26,982 options
Total stock options held by the director after this grant
Key Terms
Stock Options, 2021 Equity Incentive Plan, exercise price, expiration date
4 terms
Stock Options financial
"The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
2021 Equity Incentive Plan financial
"granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares..."
exercise price financial
"Stock options have a conversion or exercise price of 1.4400 per underlying share of common stock."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The options carry an expiration date of June 30, 2036 if not exercised earlier."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did MAIA (MAIA) director Steven Chaouki report in this Form 4?
Steven M. Chaouki reported receiving a grant of stock options for 26,982 underlying shares of MAIA common stock. The award is compensation-related, not an open-market trade, and reflects additional equity-based incentives tied to the company’s 2021 Equity Incentive Plan.
What is the exercise price of Steven Chaouki’s MAIA stock options?
The exercise price of the stock options is $1.44 per share. This means Chaouki can purchase MAIA common shares at $1.44 once he exercises the options, provided he does so before they expire and in accordance with the plan’s terms.
When do Steven Chaouki’s MAIA stock options vest and become exercisable?
The options vest 100% on the June 30, 2026 grant date and are exercisable beginning as of that date. This immediate vesting structure allows the director to exercise the options any time after grant, up until their disclosed expiration date in 2036.
When do the newly granted MAIA stock options to Steven Chaouki expire?
The stock options expire on June 30, 2036, giving a 10-year term from the grant date. After that expiration date, any unexercised portion of the award lapses, and the director can no longer purchase MAIA shares under this specific option grant.
Under which plan were Steven Chaouki’s MAIA options granted?
The options were granted pursuant to MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan. This plan governs how equity awards like stock options are issued, including terms such as vesting, exercisability, and expiration for company directors and other eligible participants.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates